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Abstract: Obesity is a worldwide health problem mainly 
due to its associated comorbidities. Fibroblast growth 
factor 21 (FGF21) is a peptide hormone involved in meta-
bolic homeostasis in healthy individuals and considered 
a promising therapeutic candidate for the treatment of 
obesity. FGF21 is predominantly produced by the liver 
but also by other tissues, such as white adipose tissue 
(WAT), brown adipose tissue (BAT), skeletal muscle, and 
pancreas in response to different stimuli such as cold 
and different nutritional challenges that include fast-
ing, high-fat diets (HFDs), ketogenic diets, some amino 
acid-deficient diets, low protein diets, high carbohy-
drate diets or specific dietary bioactive compounds. Its 
target tissues are essentially WAT, BAT, skeletal muscle, 
heart and brain. The effects of FGF21 in extra hepatic tis-
sues occur through the fibroblast growth factor receptor 
(FGFR)-1c together with the co-receptor β-klotho (KLB). 
Mechanistically, FGF21 interacts directly with the extra-
cellular domain of the membrane bound cofactor KLB 
in the FGF21- KLB-FGFR complex to activate FGFR sub-
strate 2α and ERK1/2 phosphorylation. Mice lacking KLB 
are resistant to both acute and chronic effects of FGF21. 
Moreover, the acute insulin sensitizing effects of FGF21 
are also absent in mice with specific deletion of adipose 
KLB or FGFR1. Most of the data show that pharmaco-
logical administration of FGF21 has metabolic beneficial 
effects. The objective of this review is to compile existing 
information about the mechanisms that could allow the 
control of endogenous FGF21 levels in order to obtain 
the beneficial metabolic effects of FGF21 by inducing 
its production instead of doing it by pharmacological 
administration.
Keywords: beta-klotho; diet; energy metabolism; fibro-
blast growth factor 21; obesity.
Introduction
Fibroblast growth factor 21 (FGF21) increases energy 
expenditure. It thus has beneficial effects on glucose/lipid 
homeostasis and on body weight control and emerges as 
a novel therapeutic agent for the treatment of metabolic 
diseases such as obesity, type 2 diabetes and metabolic 
syndrome. In rodent and primate models of the aforemen-
tioned conditions, FGF21 has the capacity to restore gly-
cemia and lipid profile, and to improve insulin resistance 
[1, 2].
It is widely accepted that FGF21 participates in meta-
bolic homeostasis in health but its action takes on greater 
relevance in diseases.
To date, the pharmacological use of FGF21 is limited 
due to its half-life of around 1–2 h. In order to improve 
the pharmacokinetics, selectivity, and potency of FGF21, 
several laboratories have focused on designing FGF21 
analogs. Two such analogs (LY2405319 and PF05231023) 
are currently being tested in clinical trials and have yielded 
similar results: benign toxicology, decreased plasma TGs 
and low-density lipoprotein cholesterol, increased high-
density lipoprotein cholesterol, modest weight loss, ele-
vated adiponectin, reduced insulin levels, and elevated 
plasma ketones. Surprisingly, no glucose-lowering effect 
was registered in any trial. This is a major setback as 
both compounds were assessed mainly as anti-diabetic 
drugs. However, the results of these two trials highlight 
the capacity of FGF21 to ameliorate lipid and cholesterol 
metabolism [3–5].
Nutritional signals play an important role in con-
trolling gene expression in mammals. Macronutrients 
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[carbohydrates, fatty acids (FAs), proteins], micronutri-
ents (minerals and vitamins), and some bioactive dietary 
compounds have the capacity to regulate gene expres-
sion and thus metabolic homeostasis. In this context, 
it has been described that endogenous FGF21 levels are 
regulated by various nutritional challenges such as high-
fat diets (HFDs), low-protein diets (LPDs), amino acid-
deficient diets, fasting, and polyphenols [6, 7] (Figure 1). 
However, the levels of this molecule are also determined 
by metabolic stress, including obesity, type 2 diabetes 
(T2DM), and non-alcoholic fatty liver disease (NAFLD) 
[8]. In this regard, this review summarizes how various 
nutrient stimuli and diet components regulate the 
expression of FGF21, and it also seeks to shed light on 
the molecular mechanisms and the clinical implications 
of the crosstalk between diet composition FGF21 levels 
and signaling.
FGF21 signal transduction
FGF21, together with FGF15/19 and FGF23, is an atypical 
member of the fibroblast growth factor (FGF) family. With 
endocrine, paracrine and autocrine properties, FGF21 
lacks the heparin domain present in the rest of the family 
members, thus allowing it to be secreted. Defined as a 
hepatokine, myokine, and adipokine, FGF21 is expressed 
in several tissues, including the liver, pancreas, thymus, 
heart, testis, skeletal muscle, white adipose tissue (WAT), 
brown adipose tissue (BAT), heart, and brain. It also exerts 
action on multiple target tissues, ranging from peripheral 
to central [9].
FGF21 acts as a hormone-like peptide and its signal-
ing pathway requires FGF21 binding to a fibroblast growth 
factor receptor (FGFR). FGFRs are tyrosine kinase recep-
tors, and seven isoforms have been described (1b, 1c, 2b, 
2c, 3b, 3c and 4). FGFR1c has been defined as the main 
mediator of FGF21 response in vivo [10] through an obli-
gate dimerization with the co-receptor β-klotho (KLB) [11]. 
The co-expression of these two receptors determines the 
sensitivity of a tissue or organ to FGF21 signaling.
Regarding the signal transduction pathway, the 
binding of FGF21 to the FGFR-KLB dimer stimulates the 
phosphorylation of FGFR substrate 2α (FRS2α) and the 
activation of extracellular signal-regulated kinase 1/2 
(ERK1/2) and Akt [12].
Figure 1: FGF21 expression is regulated by diet and its effects are widely distributed.
Endogenous levels of FGF21 are regulated by different macronutrients and bioactive dietary compounds. Acting as a hormone, FGF21 
impacts on several tissues where regulates mainly lipid and glucose metabolism.
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FGF21 as a hepatokine, myokine, adipokine 
and other kines
Liver production and secretion
The main source of FGF21 is the liver, where its expres-
sion is induced in response to stress. FGF21 was ini-
tially described as a fasting-adaptation hormone, as its 
hepatic production coupled to plasma levels is dramati-
cally increased during prolonged fasting [13, 14]. It is now 
known that hepatic FGF21 expression is also induced in 
other liver-stress circumstances such as in obesity, spe-
cific nutritional conditions, liver injury, viral infection, 
chemical insult, hepatosteatosis, steatohepatitis, NAFLD, 
cirrhosis, and liver cancer [8, 15–18].
Hepatic overexpression of FGF21 triggers ketogenesis, 
gluconeogenesis, and FA oxidation (FAO) and suppresses 
lipogenesis in the liver [15, 19]. However, the autocrine 
effects of FGF21 on this organ are still under debate. FGFR4 
is the predominant isoform in the liver, but the FGFR4-KLB 
complex cannot activate the FGF21 transduction pathway 
[10]. In contrast, hepatic FGFR1 levels are low, and it is 
unclear whether they are enough to ensure FGF21 signal-
ing. Later studies reported contradictory results regarding 
the role of FGF21 in ketogenesis, thereby suggesting that 
the physiological effects of this molecule may differ from 
the pharmacological ones.
As a hepatokine, FGF21 affects WAT and BAT, tissues 
in which it regulates lipid metabolism – mainly by induc-
ing lipolysis and browning and by increasing thermogenic 
capacity [20, 21]. It also exerts action in the brain, where 
it is able to reduce physical activity, induce torpor, and 
regulate circadian behavior [22, 23]. In conclusion, all 
data indicate that FGF21 is produced and secreted by the 
liver when the function of this organ is compromised by 
stress and that it is responsible for restoring and maintain-
ing metabolic homeostasis. Hepatic FGF21 expression is 
highly sensitive to nutritional status, and the molecular 
mechanisms that modulate its expression in the liver will 
be reviewed in the following chapter.
White adipose tissue: autocrine and paracrine effects
Adipose tissue is the main target tissue of FGF21 and the 
major mediator of its beneficial effects. While the physi-
ological effects of FGF21 during fasting remain elusive, 
most data on its signaling in WAT derive from studies in 
which it was pharmacologically administered or over-
expressed in obese mice. Nevertheless, FGF21 shows 
paradoxical actions on WAT depending on its source. 
Fgf21-over expressing mice show induced lipolysis [13, 
24]. In contrast, Fgf21-knockout mice present enhanced 
lipolysis in late fasting [21]. In addition, while FGF21 sup-
presses lipolysis in mouse and human adipocytes [25], it 
is induced by peroxisome proliferator activating receptor 
g (PPARg) in WAT upon feeding, thus stimulating adipo-
genesis [26, 27].
Regarding glucose metabolism, FGF21 induces 
glucose uptake in 3T3L1 adipocytes by increasing glucose 
transporter 1 (GLUT1) independently of insulin action [2, 
28]. Moreover, later studies showed increased glucose 
uptake in both WAT and BAT of lean mice infused with 
FGF21 and fed a chow diet [29].
In summary, in WAT, FGF21 induces genes involved 
in glucose uptake, lipogenesis and lipolysis, depending 
on the metabolic state of the adipocytes. These appar-
ently contradictory effects may be due to compensatory 
effects of genetic modifications in mice, different nutri-
tional status and different FGF21 concentrations reached 
between pharmacological administration and physiologi-
cal secretion.
WAT is not only a FGF21 target tissue but also a media-
tor of the effects of this growth factor. In this regard, the 
glucose- and insulin-sensitizing effects of FGF21 require 
the production and secretion of adiponectin from WAT. 
Accordingly, FGF21 stimulates this mechanism in rodents, 
and adiponectin-knockout mice fail to reproduce the sen-
sitizing effects of FGF21 [30]. Similarly, FGF21 also reduces 
the levels of the sphingolipid ceramide. Sphingolipid 
ceramides have been associated with insulin resistance 
caused by lipotoxicity. By inducing adiponectin secretion, 
FGF21 diminishes the accumulation of ceramides in obese 
animals [31]. Overall, despite some contradictory effects of 
FGF21 in adipose fat depots, adipose tissue is considered 
indispensable for the physiological and pharmacological 
effects of FGF21.
Finally, FGF21 induces the expression of uncoupling 
protein 1 (Ucp1), thus producing the so-called browning 
process of WAT in an autocrine, paracrine or endocrine 
fashion [20, 32]. Browning occurs in multilocular beige 
adipocytes in specific susceptible WAT depots, such as 
inguinal and perirenal tissue, through an increase in 
the expression of genes involved in thermogenesis and 
confers a brown fat-like phenotype to white adipocytes.
Brown adipose tissue: FGF21 induces thermogenic 
capacity
BAT is a FGF21 target tissue since it expresses FGFR1 and 
KLB; however, it is also a source of FGF21. In BAT, FGF21 
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stimulates glucose uptake and thermogenesis through the 
induction of UCP1 in the interscapular depot in an auto-
crine and paracrine fashion [33]. Upon cold exposure, 
FGF21 expression is increased in BAT and other cold-
sensitive fat depots in the β-adrenergic/ATF2-dependent 
pathway [32–34]. In this regard, Fgf21-deficient mice 
respond poorly to cold exposure and show greater shiver-
ing [32]. The mechanisms underlying the action of FGF21 
on BAT/WAT are still not well understood. Part of the 
FGF21-induced activation of the thermogenic program is 
driven by PGC1a, as FGF21 increases the protein levels of 
this molecule. Similarly, Pgc1a-knockout mice show an 
impaired response to FGF21 [32].
Furthermore, hepatic FGF21-mediated thermogenesis 
has also been described in response to maternal milk con-
sumption in neonatal pups [35], and also in situations of 
metabolic stress, for example upon amino acid restriction 
[20]. These observations suggest that the hepatic FGF21-
mediated increase in thermogenic capacity is an adaptive 
response to metabolic stress.
It has been proposed that the effect of FGF21 on 
energy expenditure and weight loss may be due to an 
increased thermogenic capacity of BAT and WAT (brown-
ing). However, recent experiments in Ucp1-null mice and 
interscapular BAT-excised mice show that when FGF21 is 
administered pharmacologically, UCP1 is not required for 
the improvement of the glucose, cholesterol, and free FA 
profile. Nonetheless, the increment in metabolic rate asso-
ciated with the administration of FGF21 is diminished in 
these mice [36–38]. These data suggest that the metabolic 
benefits of FGF21 are partly UCP1-independent.
Skeletal muscle: FGF21 is produced in response to 
mitochondrial dysfunction
FGF21 expression in muscle was first described in Akt1 
transgenic mice in which the mRNA and serum levels 
of FGF21 were induced [39]. In normal conditions, basal 
expression of FGF21 in skeletal muscle is low but its 
expression is increased by insulin [39, 40], exercise [41], 
mitochondrial myopathies [42], impaired mitochondrial 
FAO [43], muscle-specific autophagy deficiency [44] and 
transgenic overexpression of Akt1, perilipin-5 [45] or Ucp1 
[46] in skeletal muscle. The induction of FGF21 in muscle 
due to a metabolic dysfunction is driven by the tran-
scription factor ATF4, which is activated by endoplasmic 
reticulum (ER) stress. The AMPK and PI3K/Akt1 signaling 
pathways are also able to increase FGF21 expression [43].
The impact of FGF21 on skeletal muscle is not clear, as 
the expression levels of KLB do not seem to be sufficient 
to respond to FGF21. Several studies suggest that FGF21 
administration can improve glucose uptake in vitro [47, 
48], and a model of impaired mitochondrial FAO has 
recently shown the same in vivo [43].
In contrast, the role of FGF21 as a myokine is more 
evident. In the abovementioned conditions where 
FGF21 is overexpressed in muscle, the plasma levels of 
this growth factor also increase. The metabolic effects 
of this increase include the reduction of fat content in 
liver, increased FAO, resistance to a HFD and brown-
ing of WAT. These results show that FGF21 can act as a 
myokine when secreted in response to muscle stress and 
that it exerts its effects on metabolism in an endocrine 
fashion.
Heart: FGF21 exerts cardioprotective actions
Initially, the heart was discarded as a target tissue or 
source of FGF21 due to the low levels of FGF21 and KLB 
mRNA detected in this organ. However, later studies 
showed that FGF21 is expressed and secreted by cardiac 
cells in response to various stress conditions, including 
obesity, type 1 diabetes, fasting, ER stress, inflamma-
tion, infarct or hypertrophy, and some cardiovascular 
diseases [49, 50]. In the heart, FGFR1 and KLB have 
been detected in cardiac cells, where FGF21 exerts pro-
tective effects in an autocrine and endocrine fashion. 
The mRNA expression of FGF21 in these cells is driven 
by the transcriptional activation of Sirtuin1 – peroxi-
some proliferator-activated receptor a (Sirt1-PPARa) 
[50]; however, it can also be regulated by ATF4, espe-
cially when FGF21 induction is caused by ER or oxida-
tive stress [49, 51].
It is now well established that FGF21 plays a key role 
in cardiac remodeling and pathophysiology. FGF21 pro-
tects cardiomyocytes from hypertrophy through a mecha-
nism that involves the activation of the cAMP responsive 
element binding protein (CREB), the induction of PGC1a 
expression, and the reduction of the NF-kB pro-inflam-
matory pathway [50]. Cardiac FGF21 also induces the 
expression of anti-oxidant genes such as Ucp3 and 
superoxide dismutase (Sod2), thus preventing the pro-
duction of reactive oxygen species (ROS) in cardiac cells 
and oxidative stress in the heart [52]. In an autocrine 
fashion, FGF21 modulates cardiac lipid homeostasis [49] 
and protects against diabetes-induced cardiomyopathy 
by activating the ERK-p38MAPK-AMPK pathway [50]. 
Finally, as an endocrine peptide, FGF21 can also inhibit 
cardiomyocyte apoptosis, thus reducing damage to the 
heart [53, 54].
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Central nervous system: target tissue of FGF21
FGF21 has the potential to act in the central nervous 
system (CNS) since FGFRs are widely expressed in this 
tissue and KLB is specifically expressed in the suprachias-
matic nucleus, the dorsal vagal complex of the hindbrain, 
the area postrema, the nucleus tractus solitari, the nodose 
ganglia, and the paraventricular nucleus [22, 55, 56]. 
Immunoblotting experiments have revealed that FGF21 
is expressed in several regions of the brain, such as the 
substantia nigra, striatum, hippocampus, and cortex [57]; 
however, this growth factor also crosses the blood brain 
barrier and is present in the cerebrospinal fluid in a linear 
relationship with serum levels [58]. FGF21 modulates cir-
cadian rhythm and fertility [22, 59], but current data point 
to the CNS as a mediator of the effects of FGF21 on energy 
expenditure and browning [60]. However, in all cases, the 
presence of KLB appears to be required for FGF21 to exert 
its effects. This observation thus indicates that this growth 
factor is an endocrine signal. Regarding the effects of 
FGF21 on energy expenditure and browning, experiments 
with diet-induced obese (DIO) mice show that the lack of 
KLB in the CNS abrogates all the effects of FGF21 on body 
weight, insulin sensitivity, metabolic regulation in liver, 
WAT, and BAT. These data suggest that direct signaling in 
the CNS causes an increase in the sympathetic outflow.
In the hypothalamus, FGF21 affects the expression 
of corticotropin-releasing factor. Intracerebroventricular 
injection of FGF21 in Fgf21-KO mice restores the metabolic 
effects of FGF21 essentially through the corticotropin-
releasing hormone (CRH) and the activation of CREB, 
which finally enhances hepatic gluconeogenesis and 
sympathetic nerve activity in BAT [56, 61, 62]. According 
to that, lack of KLB in the brain blunts these effects [56, 
60, 61]. Finally, treatment with the b-blocker propranolol 
diminishes the effects of FGF21 when it is centrally admin-
istered but not when delivered peripherally [60].
Given the wide range of biological processes regu-
lated by the CNS and the capacity of FGF21 to act in the 
brain, it is likely that future studies will reveal new actions 
of FGF21 signaling through the CNS.
Pancreas: FGF21 preserves b-cell function
FGF21 is highly expressed in the pancreas and has pro-
tective effects against cerulein-induced pancreatitis [63]. 
Supporting data show that FGF21-deficient mice are 
more susceptible to damage, and FGF21-overexpressing 
mice are partly protected. In addition, FGF21 may be 
involved in enhancing islet engraftment [64] and in the 
preservation of b-cell function and survival [65]. Another 
point is that KLB expression is critical for these beneficial 
effects, but the expression of KLB is reduced when islets 
are treated with high glucose concentrations [66]. In the 
pancreas, FGF21 increases insulin content and glucose-
dependent secretion and inhibits glucagon release in iso-
lated islets [65].
Other effects of FGF21
In addition, and consistent with its metabolic benefits, 
FGF21 transgenic overexpression extends lifespan in 
mice. The authors of that study proposed that inhibition of 
the GH/IGF-1 signaling pathway would explain life exten-
sion in Fgf21 transgenic mice. Furthermore, microarray 
analysis showed that FGF21 modulates gene expression in 
the liver in a similar manner to caloric restriction (which 
is known to extend lifespan in mammals). These data 
suggest that FGF21 extends lifespan by acting as a selec-
tive caloric restriction mimetic in the liver [67].
Interestingly, FGF21 appears to be not only a meta-
bolic regulator but also a nutrient intake and taste regu-
lator. Both pharmacologic administration and hepatic 
secretion of FGF21 produce a satiety signal that sup-
presses the intake of “sweets” [68, 69]. In addition, two 
genome-wide meta-analyses associated genetic variations 
in a locus including Fgf21 with significant differences in 
macronutrient intake [6, 70].
While FGF21 boasts numerous beneficial effects, 
a major adverse effect is a decrease in bone mass. Both 
genetic overexpression of Fgf21 and pharmacological 
administration of this molecule lead to the inhibition of 
osteoblastogenesis and the stimulation of adipogenesis. 
In contrast, the absence of Fgf21 leads to a high bone mass 
phenotype. The mechanism underlying bone mass loss 
is the potentiation of PPARg activity [71]. Although this 
non-desirable effect has been described only in rodents, it 
has to be taken into account when considering FGF21 as a 
potential drug candidate.
FGF21 expression is regulated by nutrition
Fasting and feeding
FGF21 is expressed and produced by multiple tissues. 
However, under normal physiological conditions, all 
circulating protein appears to derive from the liver [72]. 
FGF21 was initially described as a protein induced in the 
liver to control metabolic adaptation to long periods of 
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starvation. This mRNA induction goes through the PPARa 
[13, 73, 74] and CREBH [75, 76]. Later, several studies 
showed that FGF21 expression is regulated not only by 
fasting but also by other nutritional states [77]. In addi-
tion to PPARa and CREBH FGF21 expression responds 
to the retinoic acid (RA) receptor b (RARb) [78], the RA 
receptor-related orphan receptor a (RORa) [79], the thyroid 
hormone receptor b (TRb) [80], the activating transcrip-
tion factor-4 (ATF4) [81], the farnesoid X receptor (FXR) 
[82], and the carbohydrate responsive element binding 
protein (ChREBP) [83]. The following chapter will sum-
marize the effects of various macronutrients and bioactive 
dietary components on FGF21 expression, the metabolic 
consequences and the putative signaling transduction 
pathways involved.
Carbohydrates upregulate FGF21 expression
Hepatic FGF21 is induced by prolonged fasting and also 
by refeeding with a high carbohydrate diet (HCD) (mixed 
sugar and starch) [84]. Rats starved for 24  h and refed 
with a HCD for 12  h show an increase in hepatic mRNA 
and serum levels of FGF21 and metabolic adaptations in 
the liver and WAT. Specifically in liver, there is an induc-
tion of lipogenesis, glucose uptake and metabolism, and a 
reduction of FA uptake and FAO. Similarly, in WAT, refeed-
ing with a HCD induces lipogenesis, glucose uptake and 
metabolism, and lipolysis [84]. These results support the 
hypothesis that FGF21 is produced to compensate any 
imbalanced nutritional states.
Hepatic FGF21 mRNA expression and plasma levels 
are also induced in male C57BL/6 mice fed a HC diet con-
taining 77% of energy as dextrose, 0.5% as fat and 22.5% 
as protein [85]. These results agree with previous studies 
performed in isolated rat hepatocytes cultured with high 
glucose [86]. Under this dextrose-rich diet, the liver induc-
tion of FGF21 increases de novo lipogenesis, probably as 
a result of excess carbohydrate intake. In contrast, the 
same diet supplemented with exogenous lipids [a soybean 
oil-based emulsion that is rich in C-18:1 and C-18:2 (n–6) 
unsaturated FAs] reduces FGF21 mRNA levels and de novo 
lipogenesis.
In rodents and humans, glucose is not the only mol-
ecule able to induce FGF21 expression in vitro. The human 
promoter of FGF21 responds to xylitol [77] and fructose [87] 
through the transcription factor ChREBP, which binds to a 
carbohydrate response element (ChoRE) present in human 
and mouse promoters [77, 83]. These data again reveal the 
independent mechanisms that regulate the expression of 
FGF21 downstream of fasting and feeding signals. In vivo, 
both in humans and rodents, fructose ingestion, but not 
glucose, leads to an increase of FGF21 serum levels, which 
peak 2 h after an acute load [87]. In this case, the remain-
ing question is how and why FGF21, which is considered a 
metabolic positive hormone, is induced by a metabolically 
pernicious sugar such as fructose.
Finally, it has also been demonstrated that FGF21 
expression is regulated by dietary fiber. The intake of 
such fiber facilitates weight loss and improves lipid and 
glucose profiles. Sugarcane fiber (SCF: 85% insoluble 
fiber, 70% particles  < 1 mM) administered to mice fed a 
HFD for 12 weeks enhances insulin sensitivity, diminishes 
fasting plasma glucose and TGs, and attenuates weight 
[88]. Without altering caloric intake, SCF regulates leptin 
and glucagon-like peptide 1 (GLP-1) in these mice. In the 
liver, SCF decreases TGs, cholesterol content, and FGF21 
expression, but induces mRNA levels of KLB, FGFR1, 
FGFR3 and PPARa, thus enhancing FGF21 signaling and 
ameliorating the obesity observed in the FGF21-resistant 
state. In parallel SCF also increases AMPK signaling [88].
High-fat diets induce FGF21 resistance
The notion of crosstalk between HFDs and FGF21 expres-
sion is controversial probably because of the variety of FAs 
included in diets. For example, mice fed a corn-oil based 
HFD (cHFD) for 5 weeks express more FGF21 in liver than 
those fed a HFD in which corn-oil is replaced by a fish-
derived long-chain polyunsaturated n-3 FA (PUFA) [89]. 
Moreover, another study reported that mice fed a HFD 
for 16 weeks show no differences in FGF21 mRNA levels 
versus those fed a low-fat diet [85].
In HepG2 cells, oleate, linoleate and trans-10, cis-12 
conjugated linoleic acid (t-10, c-12-CLA) induce FGF21 
expression and secretion while palmitate has no effect 
[90, 91]. Lipid infusion in humans increases the circu-
lating levels of FGF21 [90]. Similarly, in neonatal mice, 
hepatic FGF21 expression is induced at the initiation of 
suckling, mainly due to the high FA content of milk [35]. 
In this case, the FGF21 secreted induces the thermogenic 
program in BAT.
In the abovementioned situations, mRNA induction 
occurs through the activation of PPARa and causes an 
increase in serum levels of FGF21.
In addition to long-chain FAs, butyrate and α-lipoic 
acid also modulate FGF21 expression in the liver. The 
former is produced mainly by bacterial fermentation of 
dietary fiber in the large intestine, and its effect on FGF21 
expression seems to be due to its capacity to inhibit 
histone deacetylase-3 (HDAC3) [92]. Another short FA, 
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α-lipoic acid, is also involved in the regulation of FGF21. 
α-lipoic acid can be obtained from the diet (leafy green 
vegetables and red meats), and its dietary supplementa-
tion induces hepatic and plasma levels of FGF21 in vivo 
and in vitro [93, 94]. The effect of α-lipoic acid on FGF21 
expression depends on a CREBH-dependent mechanism 
that includes the induction of its expression and an 
increase in its binding to the FGF21 promoter [95].
Finally, several models of obesity in rodents, primates 
and humans showed that FGF21 levels are higher than 
in normal weight littermates [17, 96, 97]. In this context, 
obesity can be defined as an “FGF21-resistant state” [98]. 
The hepatic induction of FGF21 mRNA in DIO mice posi-
tively correlates with an attenuated responsiveness in 
liver and WAT as a result of a reduction in FGFR1, FGFR4 
and KLB levels.
Amino acid-deficient and low-protein diets increase 
energy expenditure
Several studies have described that hepatic FGF21 is reg-
ulated by protein intake. In general, LPDs or diets defi-
cient in a specific amino acid (i.e. leucine or methionine) 
cause an increase in the hepatic expression and serum 
levels of FGF21. In this regard, diets with a relatively low 
content of essential amino acids, such as many vegan 
diets, are known to be protective against cancer, auto-
immunity, obesity, and diabetes. These benefits could be 
partly due to increased circulating levels of FGF21 [99]. 
Several studies have demonstrated that FGF21 is the link 
between imbalanced amino acid intake and adaptive 
metabolic response and that it serves to restore metabolic 
homeostasis.
In liver – but not in WAT or BAT–, FGF21 is induced 
by leucine deprivation. In wild-type mice, the metabolic 
response to leucine deprivation includes dramatic changes 
in lipid metabolism. In liver, such deprivation inhibits 
FA synthase (FAS) activity, decreases the expression of 
lipogenic genes, and increases the mobilization of lipid 
stores. In WAT, it decreases FAS activity and the expres-
sion of lipogenic genes and increases the expression of 
FAO genes. Finally, there is an induction of UCP1 expres-
sion in BAT [20, 100, 101]. In contrast, in Fgf21-deficient 
mice this metabolic response to leucine is impaired, thus 
indicating that FGF21 is a key hormone in the regulation of 
lipid metabolism during leucine deprivation [20, 81].
In the same way, methionine-deprived mice show a 
comparable phenotype to that of leucine deprivation. The 
metabolic response to methionine deficiency includes 
resistance to diet-induced obesity, improved glucose 
homeostasis, increased FA activation and oxidation in 
liver, increased lipolysis in WAT, and increased Ucp1 
expression in BAT [102–104]. All these effects are coupled 
to an increase in FGF21 levels.
The metabolic response to protein restriction is 
similar to that observed under leucine or methionine 
restriction [7]. Serum levels of FGF21 increase in both 
rodents and humans upon exposure to LPDs, regardless 
of overall caloric intake [105, 106]. Protein restriction is 
accompanied by weight loss and an increase in both food 
intake and energy expenditure. Remarkably, neither food 
intake nor energy expenditure of Fgf21-deficient mice 
are altered by the administration of LPDs [7]. Moreover, 
ketogenic diets (KDs), which are widely known to induce 
FGF21 expression, are usually low in carbohydrates and 
proteins but rich in fat. The protein content of KDs under-
lies the increased levels of circulating FGF21, since protein 
supplementation but not carbohydrate supplementation 
blunts the induction [107]. This effect could also explain 
the induction of FGF21 observed in HCDs, which are char-
acterized by a low protein content.
Protein undernutrition caused by LPDs or imbalanced 
diets (which are common in mammals confronted with 
deficient sources of certain amino acids like legumes, 
grains or corn) strongly affects aminoacidemia. Addition-
ally, pathological situations caused by various forms of 
stress, such as trauma, thermal burning, sepsis and fever, 
can lead to a negative nitrogen balance. In this context, 
several scenarios that alter aminoacidemia also lead to 
an increase in FGF21 expression. The absence of slc6a19 
(neutral amino acid transporter) causes a lack of systemic 
neutral amino acids, resulting in an increase in FGF21 
transcription [108]. The treatment with the antileukemic 
agent asparaginase depletes circulating asparagine and 
glutamine levels, promoting FGF21 expression [109], and 
the skeletal muscle-specific knockout mice for glucocorti-
coid receptor (GR) show reduced alanine flux from skeletal 
muscle during fasting, resulting in an increase in FGF21 
plasma levels [110]. Hence, it is likely that many other situ-
ations that reduce amino acid availability also lead to an 
induction of FGF21 expression.
GCN2, a kinase that acts as a sensor of amino acid 
supply [111], and PPARa are indispensable for the induc-
tion of FGF21 in response to protein restriction. In this 
regard, the respective knockout mice present blunted 
induction of FGF21 when fed a LPD. Nevertheless, it is 
worth mentioning that in both Ppara-KO and Gcn2-KO 
mice, the LPD still induces FGF21 expression [7]. This 
observation suggests that additional signaling pathways 
are involved in triggering the increase in FGF21 expression 
in response to protein restriction.
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To date, there is no evidence of PPARa activation in 
response to a LPD, thus suggesting that PPARa plays a 
role in the constitutive expression of FGF21. In contrast, 
the LPD increases GCN2-dependent phosphorylation of 
eIF2a, resulting in greater ATF4 protein levels [100, 112]. 
Therefore, the GCN2/eIF2a/ATF4 cascade emerges as the 
main signaling pathway in the induction of FGF21 by 
protein restriction. ATF4 directly or indirectly induces the 
transcription of a subset of specific target genes, includ-
ing FGF21, to modulate many cellular processes to adapt 
to amino acid deficiency [81, 113, 114]. The 5′ regulatory 
region of the human FGF21 gene contains two evolutionar-
ily conserved functional ATF4-binding sequences (AARE), 
which are responsible for ATF4-dependent transcriptional 
activation in response to ER stress or amino acid restric-
tion [81, 115].
Hepatic mTORC1 activity is also related to FGF21 
expression. The mTOR signaling pathway monitors amino 
acid sufficiency and promotes protein translation and cell 
growth, among other processes [116]. In this case, L-Tsc1 
KO mice, which present mTORC1 hyperactivity in the liver, 
show increased expression of FGF21 and depleted levels 
of glutamine [117]. Moreover, when these animals are 
treated with rapamycin (mTORC1 inhibitor) or glutamine, 
the increase in FGF21 is blunted. Finally, in human 
hepatic tumors, mTORC1 activation also correlates with 
FGF21 levels [117]. It has been proposed that the mecha-
nism underling the increase in FGF21 expression occurs 
through PGC1a; however, additional mechanisms could 
be involved and it is feasible that depleted glutamine 
levels trigger an amino acid response (AAR).
In summary, amino acid-deficient diets diminish 
aminoacidemia and trigger AAR, thereby resulting in ele-
vated FGF21 levels. The contribution of each single amino 
acid to the modulation of FGF21 and how a deficiency in 
specific types of dietary protein alters FGF21 expression 
require further study.
Bioactive dietary compounds affect FGF21 expression 
and signaling
Polyphenols are the most abundant phytochemicals in 
nature. These bioactive compounds are synthesized as 
secondary metabolites by plants and are thus abundant 
in fruits, vegetables, legumes, cocoa and some beverages, 
such as tea, coffee and wine. Polyphenols comprise a large 
heterogeneous group of chemical structures, all with a 
phenolic ring with one or more hydroxyl groups, and they 
are classified mainly into two families, namely flavonoids 
and non-flavonoids, and also into many subfamilies. 
Flavonoids are the most abundant polyphenols and con-
sequently those most greatly ingested in human diets.
Due to the diversity of polyphenols, their absorption 
in the body is dose- and type-dependent and their effects 
are related to their bioavailability and pharmacokinet-
ics. It is estimated that most of the polyphenols ingested 
go directly to the colon and only between 5 and 10% are 
absorbed in small intestine. The effects of polyphenols 
in the colon have been related to a prebiotic capacity, 
as they are believed to induce the growth and activity of 
some bacteria, such as Bifidobacterium, Enterococcus 
and Prevotella. Furthermore, once absorbed, polyphenols 
enter portal circulation and are metabolized in the liver. 
Finally, the conjugate metabolites reach the bloodstream 
and the target tissues [118, 119].
Various epidemiological studies have reported that 
the regular consumption of polyphenols has beneficial 
effects in obesity, insulin resistance, cardiovascular dis-
eases, and cancer. Several lines of evidence support the 
notion that polyphenol-rich diets play a key role in regu-
lating lipid and glucose metabolism and are thus pivotal 
in the prevention and treatment of pathologies related to 
energy homeostasis [120–123].
It has been described that resveratrol has a protective 
effect on cardiovascular risk associated to ROS overpro-
duction but also on the prevention of hepatic steatosis 
and the improvement of insulin resistance [124]. Green tea 
polyphenols, mainly epigallocatechin-3-gallate (EGCG), 
reduce the LDL and increase HDL levels in humans and 
improve insulin sensitivity in genetic models of insulin 
resistance, thus exerting a beneficial effect on body weight 
and lipid profile [125, 126]. Isoflavones and polyphenol-
rich grape extract can partially prevent hepatic steatosis 
associated with obesity by restoring the correct secretion 
of adipokines – mainly leptin and adiponectin, by up-
regulating FAO, and by down-regulating lipogenesis in 
adipose tissue [127, 128].
For many years, the health benefits of polyphenols 
were attributed to their anti-oxidant capacity as free 
radical scavengers. It has recently been described that 
polyphenols activate cell-signaling pathways that are not 
related to ROS production but rather those involved in 
metabolic regulation. It is remarkable that most of these 
pathways are downstream of FGF21. It has been reported 
that, in vitro, polyphenols downregulate SREBP-1c and its 
main target genes in lipogenesis, namely FAS and acetyl-
CoA carboxylase (ACC) [129]. Stilbens, mainly resveratrol, 
exert their effects by promoting the phosphorylation and 
activation of the AMP-activated protein kinase (AMPK) and 
the activity of SIRT and PGC1a, thus inducing FA catabo-
lism through the AMPK/SIRT1/PGC1a axis [130,  131]. On 
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the other hand, an anthocyanin-rich juice extract up-regu-
lates PPARa activity in mice on a HFD and down-regulates 
lipogenic gene expression in liver by promoting FA con-
sumption. Coffee polyphenols and resveratrol also induce 
FAO in rats through PPARa and PGC1a-dependent mecha-
nisms [132]. Chalcones and flavokawain cardamonin type 
B inhibit lipid accumulation and adipocyte differentiation 
by increasing the phosphorylation of the ERK in the early 
phase of adipogenesis [133].
In summary, polyphenols exert beneficial metabolic 
effects especially in obese and in insulin-resistant animal 
models, and FGF21 restores homeostasis in scenarios of 
metabolic stress. The crosstalk between the two signals 
remains unclear, but a positive correlation between the 
beneficial effects of polyphenol-rich fruit extracts and 
FGF21 activity has been described in various rodent 
models of diet-induced obesity. In some cases, the effects 
of polyphenols were due to an induction of FGF21 levels 
in liver [134, 135] but also to an enhancement of FGF21 
signaling by increasing the expression of FGF21 receptors 
and KLB, [136, 137]. Moreover, flavokawain B and carda-
monin also modulate the secretion of FGF21 in mature 
adipocytes [133].
FGF21 in humans
After the identification of rodent FGF21 as an endocrine 
regulator induced downstream of PPARa and its agonists 
by both fasting and a KD [13, 73], it was shown that fasting 
FGF21 levels are significantly increased in patients with 
T2DM without a correlation with BMI, thereby pointing 
to a potential role of FGF21 in the pathogenesis of insulin 
resistance and T2DM [138].
Later, in contrast to previously published data, it was 
described that serum FGF21 levels in overweight and in 
obese subjects are significantly higher than in lean indi-
viduals and that they correlate positively with adiposity 
and the metabolic syndrome [17, 139]. Also, an increase 
in plasma levels of FGF21 in hepatic- and muscle-insulin 
resistant states and a correlation with BMI have been 
reported [140].
Accordingly, a study performed in 2010 again showed 
a positive correlation between FGF21 expression and 
BMI; however, the authors did not find that fasting and 
refeeding or 12  days of a KD regulated the hormone in 
humans [8]. Moreover, FGF21 concentrations are revers-
ibly increased and are related to leptin and free FAs in 
obese children. However, the results of that study do not 
support a significant relationship between FGF21, insulin 
resistance, and features of metabolic syndrome or NAFLD 
in this age group [141]. The same pattern of FGF21 expres-
sion was described in obese adolescents with T2DM com-
pared with obese adolescents without. As in rodents, this 
increment in FGF21 levels in obesity and T2DM points to a 
FGF21-resistant state and an impaired capacity of FGF21 
to improve insulin sensitivity [142]. No significant asso-
ciation between FGF21 and growth or IGF-1 was found in 
either cross-sectional or longitudinal analyses; these find-
ings do not support a relationship between FGF21 and 
growth in obese children [143].
In contrast, in the pubertal transition, it was found 
that FGF21 concentrations do not differ by obesity status 
or by sex. An inverse association between FGF21 and 
bone mineral content (BMC) among non-obese individu-
als and an inverse association between FGF21 and lean 
mass among females were observed, which were both 
independent of fat mass. FGF21 was inversely associated 
with HOMA-IR in males but not in females. The existence 
of relationships between FGF21, musculoskeletal para-
meters, and insulin resistance raises the possibility of 
crosstalk between these systems. These data suggest that 
circulating FGF21 differs in its association with bone, lean 
mass and insulin resistance depending on the sex and 
weight of the individual [144].
Globally, several studies have proposed FGF21 as a 
biomarker for metabolic pathologies such as cardiovascu-
lar diseases, NAFLD, and mitochondrial disease [8, 145]. 
Serum FGF21 concentrations are significantly elevated 
in patients with mitochondrial disease. This prospective 
study established serum FGF21 levels as a sensitive bio-
marker of mitochondrial disease and demonstrated that 
they are the best predictor of this disorder when compared 
to serum levels of other classical indicators [146]. In the 
same way, a cross-sectional study with a large well-char-
acterized sample (913 subjects) assessed the interaction 
between clinical parameters (renal function, metabolic, 
hepatic and vascular risk markers), as well as growth 
hormone (GH) status, with FGF21 levels. Those authors 
concluded that FGF21 serum concentrations are associ-
ated with several aspects of the metabolic syndrome, 
hepatocellular function, as well as with GH status [147].
In a healthy population, there is also an age-related 
increase in serum FGF21 levels. This observation high-
lights a potential age effect in response to metabolic 
demands during the lifespan. FGF21 levels increase with 
age independently of body composition. At lower levels 
of FGF21, bone mineral density (BMD), but not other 
body composition parameters, attenuates the association 
between FGF21 levels and age, thereby suggesting that the 
metabolic demands of the skeleton serve to link FGF21 
and energy metabolism [148].
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Regarding the nutritional regulation of FGF21 in 
humans, the data are less clear than in rodents. Increased 
levels of FGF21 in human serum after extreme fasting 
(7 days) and PPARa activation have been described in 
healthy non-diabetic individuals but with a wide inter-
individual variation. The induction of ketogenesis inde-
pendently of FGF21 levels suggests that the physiological 
role of FGF21 in humans differs from that in mice [149]. 
Although FGF21 is elevated in response to pharmacologi-
cal activation of PPARa and PPARd, the absence of varia-
tion in human plasma during fasting and refeeding and 
the decrease after a 3-month KD confirm that FGF21 does 
not play a major role in regulating fasting response or 
ketosis in humans [150].
Unlike mice, which showed an increase in circulating 
FGF21 after only 6  h of fasting, human subjects did not 
have a notable surge in FGF21 until 7–10 days of fasting. 
Moreover, FGF21 induction was associated with decreased 
thermogenesis and adiponectin, an observation that con-
trasts with previous reports based on supraphysiological 
dosing. In addition, FGF21 levels increased after ketone 
induction, thereby demonstrating that endogenous 
FGF21 does not drive starvation-mediated ketogenesis in 
humans. Instead, a longitudinal analysis of biologically 
relevant variables identified serum transaminase markers 
of tissue breakdown as predictors of FGF21. These data 
establish FGF21 as a fasting-induced hormone in humans 
and indicate that it contributes to the late stages of adap-
tation to starvation, when it may regulate the utilization of 
fuel derived from tissue breakdown [151].
A large number of studies have shown that dietary 
protein content markedly influences food intake and 
metabolism. In this context, in humans, circulating 
FGF21 levels increase dramatically after 28 days on a LPD, 
thereby suggesting that FGF21 is a signal of protein restric-
tion and providing an explanation of the effect of dietary 
protein deficiency on metabolism [7].
As mentioned earlier, FGF21 levels increase rapidly 
following fructose ingestion and return to baseline within 
5 h. Moreover, both baseline and fructose-stimulated 
FGF21 levels are 2–3 fold higher in subjects with meta-
bolic syndrome compared to those in healthy subjects. In 
contrast, FGF21 does not increase in the first 2 h after the 
ingestion of a glucose load, although a modest increase is 
observed after 3–4 h. These data suggest that FGF21 plays 
a key role in fructose metabolism in humans [87].
Other nutritional challenges that affect FGF21 levels 
are fish oil supplements and betaine. The inclusion of the 
former in a diet for 3 months markedly reduces the circu-
lating levels of FGF21 and other biomarkers, combined 
with decreases in serum lipids, glucose, liver enzymes, 
and other NAFLD risk factors. These results suggest that 
fish oil might contribute to reversing FGF21 resistance 
[152]. Regarding betaine, it is known that plasma betaine 
levels are reduced in insulin-resistant humans and that 
they correlate closely with insulin sensitivity. In this 
context, in addition to the beneficial metabolic effects of 
betaine, supplementation with this compound robustly 
increases hepatic and circulating FGF21 levels in mice. On 
the basis of these observations, betaine supplementation 
merits further investigation for the treatment or preven-
tion of T2DM in humans [153].
Circulating levels of FGF21 can also be boosted by 
exercise. Increased levels of the protein were observed 
in the serum of healthy male volunteers performing 
a treadmill run at 50 or 80% VO2max. These results 
suggest that FGF21 is also associated with exercise-
induced lipolysis [41].
Finally, in healthy human volunteers, the injection of 
natural glucagon increased plasma FGF21 within hours, 
showing for the first time that glucagon regulates glucose, 
energy, and lipid metabolism, at least in part via FGF21-
dependent pathways [154].
Expert opinion
FGF21 is a peptide hormone involved in metabolic homeo-
stasis and considered a promising therapeutic candidate 
for the treatment of obesity and associated comorbidities 
such insulin resistance, T2DM, and cardiovascular dis-
eases. Although the effects of FGF21 in humans seems to 
be weaker than in mice and interindividual variability in 
the levels of this growth factor are observed, it is obvious 
that FGF21 exerts beneficial effects on metabolic homeo-
stasis in both species. To date, the therapies related to 
FGF21 overexpression have involved pharmacological 
administration; however, this approach has considerable 
limitations due to the kinetics and bioavailability of the 
compound. Recently, several studies have demonstrated 
that specific macronutrients and bioactive dietary com-
pounds can modulate endogenous FGF21 expression and 
signaling, thereby opening up the possibility to induce 
FGF21 production or increase activity through dietary 
intervention. The most feasible approaches to define a 
nutritional intervention able to induce FGF21 activity and 
reduce obesity and associated-comorbidities are prob-
ably through protein restriction and polyphenol-enriched 
diets. However, more research is needed in order to estab-
lish the role of FGF21 as the link between the dietary com-
ponents. It is also important to highlight that all these 
nutritional interventions must be done in compliance 
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with a balanced diet in order to prevent the loss of muscle 
mass or BMD and essential nutrient deficiencies.
Outlook
To design therapeutic approaches based on a nutritional 
intervention it is essential to determine the molecular 
mechanisms through which macronutrients, micronutri-
ents, and bioactive dietary compounds affect FGF21 expres-
sion and signaling. It is likely that the  metabolic effects 
of certain diets such as vegan or the beneficial effects of 
established healthy diets, such as the Mediterranean diet, 
occur at least in part through FGF21. Further studies in 
humans will be required to define the effect of a nutritional 
profile on FGF21 levels and signaling in healthy, obese and 
T2DM patients. Also it will be important to define if there 
are any differential effects between the pharmacological 
administration of FGF21 and its endogenous overproduc-
tion. Moreover, obesity that is one of the possible diseases 
treatable with FGF21 is also a FGF21-resistant state. In 
this context it will be strictly necessary to study the way 
to overcome this resistance, thus increasing the levels of 
the FGF21 receptors in its target tissues. Some studies have 
revealed that some nutritional interventions are able to 
induce the expression of FGFR and KLB.
In summary, FGF21 is a promising therapeutic can-
didate against metabolic pathologies such as obesity or 
T2DM and its expression and signaling are highly regu-
lated by different nutritional states. The remaining ques-
tion is how we can increase the responsiveness to FGF21 in 
obese or T2DM patient just through a dietary intervention.
Highlights
In animal models has been is well described that:
 – The liver is the main organ in contributing to serum 
levels of FGF21.
 – The transcription factors network responsible for the 
control of FGF21 gene expression is highly compli-
cated. Both, positive and negative factors have been 
described.
 – The expression of hepatic FGF21 responds to several 
stimuli, mainly metabolic stress signals.
 – The hepatic expression of FGF21 can be modified by 
dietary components. Mainly high fat diet, high carbo-
hydrate diet, low protein diet or amino acid restricted 
diets.
In order to confirm FGF21 as a therapeutic candidate 
against metabolic pathologies such as obesity or T2DM:
 – The role of FGF21 as the link between the dietary 
components and its metabolic effects has to be set 
precisely.
 – The effect of dietary bioactive compounds on the 
expression of hepatic FGF21 needs further studies.
 – The mechanisms responsible for the establishment of 
the FGF21-resistant state have to be proven.
 – The effect of different dietary interventions on the 
expression of FGF21 receptors in target tissues needs 
future evaluation.
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